Partnering Opportunities

Press & News

2022-06-03

Data suggest efficacy over standard of care for the treatment of psoriatic arthritis Izokibep...[read more]

Partnering Opportunities

Affibodys partnering strategy is to engage in partnerships centered around:

Target-by-target development of novel biotherapeutics (discovery collaborations), or
Out-licensing of Albumod™ technology

For opportunities for collaborative, partnership or licensing agreements, please contact bd@affibody.com.

Affibodys latest Press releases

2022-06-03

Affibody, ACELYRIN, and Inmagene Biopharmaceuticals Announce Data from Global Phase 2 Trial of Izokibep in Patients with Psoriatic Arthritis Presented During 2022 European Alliance of Associations for Rheumatology Congress

Data suggest efficacy over standard of care for the treatment of psoriatic arthritis Izokibep was well-tolerated, having a safety...[read more]

Press & News

Affibody in short

Affibody is a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™.

About Affibody

Upcoming reports Financial calendar

Interim Report January to March 2020 (May 15, 2020)
Interim Report January to June 2020 (August 21, 2020)
Interim Report January to September 2020 (November 13, 2020)
Year End Report 2020 (February 2021)

Investor information